YK-11 will be here this BLACK FRIDAY!

[RUI-Products]

^^^click above^^^

YK11 is quite honestly the most exciting research compound to have come along in quite some time. It belongs to a category of research compounds known as SARMS (Selective Androgen Receptor Modulators). SARMs allow your research subject to get the benefits of an androgen with a marked decrease in some of the undesirable effects a normal androgen might induce. For example you might observe a marked increase in muscle without the usual adverse observation of an increase in liver values. SARMs also have a reduced impact on the HPTA, so unlike a normal androgen that would cause your research subjects HPTA to be shut down, while using a SARM you may observe simply a suppression of the HPTA. This is a very exciting property for you in your research! The phrase,” The good effects with significantly less of the bad” comes to mind!

This effect alone is exciting enough for your research purposes, however with the SARM YK11 it does not stop there, not by a long shot. YK11 also functions as an active myostatin inhibitor in your research subjects. Myostatin is a protein present in your research subjects which inhibits or limits muscle cell growth. By inhibiting myostatin the actual amount of muscle that your research subject can build is increased. The normal genetic limit is raised if you will. This is a very exciting effect when it comes to your research.

The thing that makes YK11 so interesting and desirable for your research purposes is the fact that it possesses this dual mechanism of action. While there are research compounds that work strictly as a SARM and some that work strictly as a myostatin inhibitor, YK11 affords you the opportunity to experiment and research with a compound that very effectively acts as both! This effect is, thus far, unique to the compound that is YK11. It is quite likely that YK11 could revolutionize research in your area of interest. Never before has a compound been introduced that possesses the dual effect of building more muscle while at the same time actually increasing the amount of muscle that can actually genetically be built and supported!

We are proud and excited to be able to offer you the best quality YK11 currently available for your research purposes!

LIQUID YK11 30ML 10MG/ML

[Bouncer]

a myostatin inhibitor.. something science has been working on for decades, the holy grail of the bodybuilding world if a drug could be found. I'd have to see user feedback and studies before I believe it but it's an exciting prospect none the less.

[blm]

It's technically not a SARM and there is a lot of conflicting information about it. And from what I can find no real user feedback that supports any of the claims. I looked into this a few months ago when another peptide supplier was blasting a board with unsupported claims. This is some of the information I found.

The current information on the internet about YK-11, is some what incorrect and by no means complete. YK-11 is not a SARM. It's a testosterone (Test)/ 5-α-dihydrotestosterone (DHT) derivative a synthetic anabolic steroid.*

YK-11 possess the same steroid backbone as all other chemicals classified as steroid hormones.*

To date no chemical classified as a SARMs possess a steroid backbone.*

The first peer reviewed paper on YK-11 by Kanno Y et al 2011 suggested that "YK-11 is a partial agonist of the Androgen receptor and might act as selective androgen receptor modulator " ((17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the an... - PubMed - NCBI ). A subsequent paper in 2013 by Kanno Y et al further investigating the molecular mechanics of YK-11 named it as a SARM in the papers title (Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression.). Research carried out by Kanno Y et al is scientifically sound but labelling this steroid as a SARM was incorrect.*

It can be argued that because no nomenclature (Nomenclature) exists for classifying chemicals as SARMs, calling YK-11 a SARM is justified. However a quick look at steroid nomenclature confirms YK-11 is indeed a synthetic steroid.

If not labled a SARM by mistake my guess as to why it was labled so would be would be two fold:*

1) To get media attention (but this will only snuff YK-11 out as a steroid) and*

2) To secure further funding (perhaps for animal testing) into the effects of YK-11 as research is not cheap.*

I would put my money on the second reason as being the most likely reason.

As inferred above YK-11 has no animal testing data only in vitro data on C2C12 cells obtained from mice myoblats cell line capable of differentiation. Not all muscle cells can differentiate. C2C12 experiments tell us that YK-11 has the potential to cause muscle differentiation at certain concentrations. This can't directly be translated into a human equivalent dose because we have no data on it's metabolism but we can speculate based on research we have on other synthetic steroids. But we have no safety data on it.

The internet media likely from a surface reading of papers by Kanno Y et al have concluded that YK-11 is be more potent than classic steroids and has less side effects than them. This has not been stated or proven in any of the papers on Yk-11 published by Kanno Y et al, instead it is speculated the safety parameters of YK-11 may be comparable to SARMs but no comparison has actually been made.

What we see a combination of collective enthusiasm of the people and marketing hype piggybacking on the SARM name. Make no mistake YK-11 is not a SARM and has absolutely no safety data, which you can only really get from toxicity studies using animals/humans.

Given that we now know that YK-11 is a designer anabolic steroid it likely possess the typical side effects associated anabolic steroid which we can now assigned to YK-11 >> (Anabolic steroid). YK-11 has 4 methyl (CH3) groups and so will likely prove taxing to the liver; SARMs have reduced liver toxicity profile because they have substituted methyl groups with Halocarbons. In addition, data produced by Kanno Y et al 2013 demonstrate that YK-11 induces the production of follistatin, a glycoprotein that inhibits myostatin a protein which inhibits myogenesis (the development/formation of new muscle tissue/fibers during embryonic development and also extant in adult muscle tissue). Follistatin is also associated with prostate growth and so being targeted as such (Follistatin as potential therapeutic target in prostate cancer.)*

Sparsely speculating on the potential therapeutic effects of YK-11 using existing data is by no means correct and no one should assume so without doing their own critical assessment of the information available.*

YK-11 is derivative of the anabolic steroid DHT, and as partial agonist of the androgen receptor it would activate the androgen receptor to give a submaximal response when inadequate amounts of DHT or Test are present. In the presence of overstimulation of androgen receptors say when excess amounts of DHT or Test are present YK-11 will act as a competitive inhibitor of androgen receptors . This is because partial agonists typically display both agonistic and antagonistic properties.

Current pharmacodynamic data on YK-11 present by Kanno Y et al has me speculating that YK-11 will operate as an Antiandrogen with some anabolic potential in low levels of Test/DHT.*

As a derivative of DHT, YK-11 will likely have little or no significant clinical effect on muscle mass gains, but may aid muscle mass retention with an effect on muscle hardness, muscle strength, libido and other typical masculine phenotypes because it shares a similar chemical make up and mechanism of action to DHT. Also because YK-11 was chemically designed from ethisterone a steroidal progestin (as stated in methodology section of the 2011 paper by Kanno Y et al) and also bares some chemical resemblance to steroidal progestin Norethynodrel which was the first female oral contraceptive as well as the class of steroidal progestin which followed from Norethynodrel, YK-11 will likely possess the ability to bind and activate or inhibit progestogen receptors; which comes with it's own sets of effects. However only androgen receptors have been looked at so far so it is unknown what else may YK-11 bind to.*

In healthy adult males the effects of YK-11 on muscle building quality are likely to be submaximal because it is a partial agonist on the androgen receptor and so a healthy male may experience reductions muscle strength and hardness while a female may experience improvements. However the ability of Yk-11 to increase follistatin levels compared to DHT and other steroids is what makes it novel. However no pre-clinical, clinical data exists to confirm its therapeutic significance if any.*
No chemical compound to my knowledge exists that displays follistain stimulating effects like that of YK-11 so no comparison can be made. DHT is known to have effects on the CNS (central nervous system) and so YK-11 may also possess such effects if it can cross the blood brain barrier.

To conclude, YK-11 is a synthetic steroid with anabolic and likely undiscovered progestin potential. Because YK-11 is partial agonist to the androgen receptor it will be in direct competition with Test and DHT for binding and so its anabolic activity may be reliant on its ability to stimulate follistatin. Because of its partial agonist competition with Test and DHT it may reduce anabolic activity in otherwise healthy males. To date no safety data or animal testing exist.

[Bouncer]

So according to that article, it's not a SARM but a Designer Steroid. Interesting.

[lifterjaydawg]

cool compound, I started researching it not log ago and found it acts like a myo-inhib and a sarm with anabolic effects.
my main interest is this myostatin effect which REALLY interests me.
I am thinking to use it with a cycle of test and deca and see how that goes since iv done test/deca a bunch of times I know what to expect.
I found these studies showing the mayo-inhib (more like folli expression enhanced) and the mention of being SARM>

Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression.> Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. - PubMed - NCBI

(17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor.> (17